Review for 10.1186/s12876-019-0982-4 (2019)

Reviewer ’s report  
 
Title: Methot rexate -associated lymphoproliferative disorder in the stomach and duodenum: A 
case report  
 
Version: 0 Date: 29 Aug 2018  
 
Reviewer: V. Koneti Rao  
 
Reviewer's report:  
 
Please include all comments for the authors in this box rather than uploading your report as an 
attachment. Please only upload as attachments annotated versions of man uscripts, graphs, 
supporting materials or other aspects of your report which cannot be included in a text format.  
Please overwrite this text when adding your comments to the authors.  
It is a well written case report about LPD in a  70year old woman with h /o H. pylori and RA who 
developed LPD after being on MTX 6mg weekly for 6 months.I liked the schematic diagram of 
Figure 3.  
1. Line 41, page 1: I am not sure I understand what authors mean when they say: "but 
chemotherapy based on tissue type is required i n intractable or recurrent cases". It may be 
more appropriate to say "chemotherapy may be needed to treat lymphoma recurring or 
persisting after stopping MTX treatment".  
 
2. Line 41: Lymphoma treatment does not depend on tissue type.  
 
3. Line 54; Discussio n page 1: Withdrawal of MTX results in spontaneous remission of LPD in 
25-60% of cases. Please comment how long does the remission last and how many require 
further treatment with chemotherapy like your patient.  
 
4. Line 22; Discussion page 2: Please add da ta if available about the incidence of lymphoma in 
RA patients following use of other agents in RA: Cyclosporine, Biologicals etc. Is it higher 
than baseline lymphoma rate in general population as well as RA patients not on these drugs ? 
 
5. Figure 3: Add S UV values for the serial PET scans, if available.  
 
6. Table 1: Remove this table as it does not add much value since most values are normal 
except sIL2R(already nicely graphed in figure 3) and LDH.  
  
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.  
 
Yes 
 
Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.  
 
Yes 
 
Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.  
 
Yes 
 
Are you able to assess any statistics in the manuscript or would you recommend an  
additional statistical review?  
If an additio nal statistical review is recommended, please specify what aspects require further  
assessment in your comments to the editors.  
 
Not relevant to this manuscript  
 
Quality of written English  
Please indicate the quality of language in the manuscript:  
 
Acceptable  
 
Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:  
 
1. Have you in the past five years received reimbursements, fees, funding, or salary from an  
organisation that may in any way gain  or lose financially from the publication of this  
manuscript, either now or in the future?  
 
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose  
financially from the publication of this manuscript, either now or in the fut ure? 
 
3. Do you hold or are you currently applying for any patents relating to the content of the  
manuscript?  
 
4. Have you received reimbursements, fees, funding, or salary from an organization that 
holds  or has applied for patents relating to the content of  the manuscript?  
 
5. Do you have any other financial competing interests?  
 
6. Do you have any non -financial competing interests in relation to this paper?  
 
If you can answer no to all of the above, write 'I declare that I have no competing interests' 
below.  If your reply is yes to any, please give details below.  
 
I declare that I have no competing interests.  
 
I agree to the open peer review policy of the journal. I understand that my name will be included  
on my report to the authors and, if the manuscript is ac cepted for publication, my named report  
including any attachments I upload will be posted on the website along with the authors'  
responses. I agree for my report to be made available under an Open Access Creative Commons  
CC-BY license ( http://creativecommo ns.org/licenses/by/4.0/ ). I understand that any comments  
which I do not wish to be included in my named report can be included as confidential comments  
to the editors, which will not be published.  
 
I agree to the open peer review policy of the journal